Hepatitis C drugs remain unaffordable in many countries, says WHO study

Immunotherapy Becomes Reality For Cancer
June 14, 2016
Scientists Discover Gene Responsible for Multiple Sclerosis
June 15, 2016
Show all

Hepatitis C drugs remain unaffordable in many countries, says WHO study

According to new research, treatment costs for hepatitis C remain out of reach for patients in several poor countries.

In the latest effort to quantify the burden of expensive medicines, a new study found that the cost of two widely used hepatitis C treatments remains out of reach for people in many poor countries and poses a “financial and ethical dilemma” for payers and doctors.

In general, current prices are unaffordable and, as a result, poorer countries may be paying higher prices than wealthier nations, according to the study, which appeared on Tuesday in PLOS Medicine and was conducted by World Health Organization officials. The authors examined 2015 prices for the Sovaldi and Harvoni drugs, which are sold by Gilead Sciences, in 30 countries in the Organisation for Economic Cooperation and Development.

The study found that if a patient paid for treatment out of pocket, the cost of a full course of Sovaldi alone would equal one year or more of average earnings for people in 12 countries. For instance, when adjusting for rebates, currency differences, and purchasing power, Sovaldi cost $101,000 in Poland and $70,300 in Turkey, compared with nearly $64,600 in the United States.

Read Full Article: Hepatitis C drugs remain unaffordable in many countries, says WHO study | NextBillion

Read Full Article: Hepatitis C drugs remain unaffordable in many countries, says WHO study | NextBillion

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.